Development and validation of a prediction tool to support engagement in HIV care among young people ages 10-24 years in Kenya.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
06
2022
accepted:
11
05
2023
medline:
3
7
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
epublish
Résumé
Loss to follow-up (LTFU) among adolescents and young adults living with HIV (AYALWH) is a barrier to optimal health and HIV services. We developed and validated a clinical prediction tool to identify AYALWH at risk of LTFU. We used electronic medical records (EMR) of AYALWH ages 10 to 24 in HIV care at 6 facilities in Kenya and surveys from a subset of participants. Early LTFU was defined as >30 days late for a scheduled visit in the last 6 months, which accounts for clients with multi-month refills. We developed a tool combining surveys with EMR ('survey-plus-EMR tool'), and an 'EMR-alone' tool to predict high, medium, and low risk of LTFU. The survey-plus-EMR tool included candidate sociodemographics, partnership status, mental health, peer support, any unmet clinic needs, WHO stage, and time in care variables for tool development, while the EMR-alone included clinical and time in care variables only. Tools were developed in a 50% random sample of the data and internally validated using 10-fold cross-validation of the full sample. Tool performance was evaluated using Hazard Ratios (HR), 95% Confidence Intervals (CI), and area under the curve (AUC) ≥ 0.7 for good performance and ≥0.60 for modest performance. Data from 865 AYALWH were included in the survey-plus-EMR tool and early LTFU was (19.2%, 166/865). The survey-plus-EMR tool ranged from 0 to 4, including PHQ-9 ≥5, lack of peer support group attendance, and any unmet clinical need. High (3 or 4) and medium (2) prediction scores were associated with greater risk of LTFU (high, 29.0%, HR 2.16, 95%CI: 1.25-3.73; medium, 21.4%, HR 1.52, 95%CI: 0.93-2.49, global p-value = 0.02) in the validation dataset. The 10-fold cross validation AUC was 0.66 (95%CI: 0.63-0.72). Data from 2,696 AYALWH were included in the EMR-alone tool and early LTFU was 28.6% (770/2,696). In the validation dataset, high (score = 2, LTFU = 38.5%, HR 2.40, 95%CI: 1.17-4.96) and medium scores (1, 29.6%, HR 1.65, 95%CI: 1.00-2.72) predicted significantly higher LTFU than low-risk scores (0, 22.0%, global p-value = 0.03). Ten-fold cross-validation AUC was 0.61 (95%CI: 0.59-0.64). Clinical prediction of LTFU was modest using the surveys-plus-EMR tool and the EMR-alone tool, suggesting limited use in routine care. However, findings may inform future prediction tools and intervention targets to reduce LTFU among AYALWH.
Identifiants
pubmed: 37390119
doi: 10.1371/journal.pone.0286240
pii: PONE-D-22-17238
pmc: PMC10313055
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0286240Subventions
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NICHD NIH HHS
ID : UG3 HD096906
Pays : United States
Informations de copyright
Copyright: © 2023 Wilson et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Health Serv Res. 2016 May 20;16:189
pubmed: 27206474
PLoS One. 2015 Dec 31;10(12):e0145515
pubmed: 26720412
J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):e8-e10
pubmed: 28961677
AIDS Care. 2016;28(4):500-7
pubmed: 26565428
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):333-43
pubmed: 26918545
PLoS One. 2014 Jan 15;9(1):e85774
pubmed: 24454931
J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108
pubmed: 25942461
AIDS Behav. 2018 Nov;22(11):3763-3772
pubmed: 29846836
Clin Epidemiol. 2019 May 07;11:359-373
pubmed: 31191029
BMJ Open. 2015 Sep 02;5(9):e008461
pubmed: 26338684
Dig Dis Sci. 2021 Nov;66(11):3993-4000
pubmed: 33242157
Heart. 2012 May;98(9):683-90
pubmed: 22397945
Psychiatry Res. 2007 Aug 30;152(2-3):293-7
pubmed: 17459488
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
Int J Infect Dis. 2020 Aug;97:151-158
pubmed: 32497804
J Med Internet Res. 2021 Apr 16;23(4):e25852
pubmed: 33822738
Int J Med Inform. 2017 Jan;97:68-75
pubmed: 27919397
South Afr J HIV Med. 2020 Jul 22;21(1):1077
pubmed: 32832112
AIDS. 2019 Jul 15;33(9):1501-1510
pubmed: 30932957
JAMA. 2000 Jul 5;284(1):79-84
pubmed: 10872017
J Int AIDS Soc. 2020 May;23(5):e25488
pubmed: 32438498
AIDS Behav. 2020 Dec;24(12):3320-3336
pubmed: 32715409
Health Educ Q. 1988 Winter;15(4):351-77
pubmed: 3068205
J Int AIDS Soc. 2021 Jul;24(7):e25767
pubmed: 34235876
Sex Transm Dis. 2020 Nov;47(11):760-766
pubmed: 33045165
Clin Infect Dis. 2017 Mar 15;64(6):751-758
pubmed: 28034882
Eur Heart J. 2014 Aug 1;35(29):1925-31
pubmed: 24898551
PLoS One. 2020 Feb 10;15(2):e0228370
pubmed: 32040523
PLoS One. 2016 May 18;11(5):e0154318
pubmed: 27192052
AIDS Patient Care STDS. 2019 Jun;33(6):237-252
pubmed: 31166783
Curr HIV/AIDS Rep. 2020 Jun;17(3):171-179
pubmed: 32347446
Heart. 2012 May;98(9):691-8
pubmed: 22397946
J Acquir Immune Defic Syndr. 2022 Jun 1;90(2):154-160
pubmed: 35262514
J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):42-47
pubmed: 27852944
Lancet. 2006 Oct 7;368(9543):1260-9
pubmed: 17027732
AIDS Behav. 2021 Feb;25(2):297-310
pubmed: 32651762
Public Health. 2019 Aug;173:146-149
pubmed: 31310874
BMJ Glob Health. 2016 Oct 24;1(3):e000004
pubmed: 28588949
EBioMedicine. 2017 Mar;17:163-171
pubmed: 28161401
PLoS One. 2017 Sep 29;12(9):e0184879
pubmed: 28961253
PLoS One. 2014 Nov 12;9(11):e112261
pubmed: 25390044
J Assoc Nurses AIDS Care. 2022 Mar-Apr 01;33(2):132-154
pubmed: 33654006
J Pers Assess. 1990 Winter;55(3-4):610-7
pubmed: 2280326
PLoS One. 2017 Dec 29;12(12):e0190260
pubmed: 29287088
AIDS Behav. 2022 Sep;26(9):3131-3138
pubmed: 35362907
Epidemiology. 2010 Jan;21(1):128-38
pubmed: 20010215
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):22024
pubmed: 28770588
PLoS One. 2018 Apr 18;13(4):e0195362
pubmed: 29668691
J Int AIDS Soc. 2018 Dec;21(12):e25215
pubmed: 30548817
Sci Rep. 2022 Jul 26;12(1):12715
pubmed: 35882962
BMJ Open. 2011 Feb 23;1(1):e000005
pubmed: 22021721
PLoS One. 2019 Dec 31;14(12):e0226809
pubmed: 31891601
AIDS. 2020 Jul 15;34(9):1261-1288
pubmed: 32287056
J Int AIDS Soc. 2017 Nov;20(3):
pubmed: 29178197